Comparative Pharmacology
Head-to-head clinical analysis: DURANEST versus XYLOCAINE 5 W GLUCOSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURANEST versus XYLOCAINE 5 W GLUCOSE 7 5.
DURANEST vs XYLOCAINE 5% W/ GLUCOSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
2-10 mL of a 1-2% solution, subarachnoid injection, single dose only.
Adult: 5-25 mL (250-1250 mg lidocaine) of 5% lidocaine with glucose 7.5% solution, administered by caudal or lumbar epidural injection, single dose. Max total dose: 1250 mg.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours (range 3-6 hours). Clinical context: Prolonged in severe hepatic impairment but not significantly in renal impairment.
1.5-2 hours (terminal); prolonged in heart failure, hepatic disease, or elderly; neonates 3-6 hours due to immature hepatic function.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug. Biliary/fecal elimination is minimal.
Hepatic metabolism (90% N-dealkylation by CYP1A2/CYP3A4 to monoethylglycinexylidide and glycinexylidide); renal excretion of metabolites and parent drug (<10% unchanged); <1% biliary/fecal.
Category C
Category C
Local Anesthetic
Local Anesthetic